These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 12406079)

  • 21. [Rituximab resistance in B-cell lymphoma and its elimination].
    Hatake K; Terui Y
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
    Hao LC; Zhang LZ
    Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
    [No Abstract]   [Full Text] [Related]  

  • 23. Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses.
    Serke S; Schwaner I; Yordanova M; Szczepek A; Huhn D
    Cytometry; 2001 Apr; 46(2):98-104. PubMed ID: 11309819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
    Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
    Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab therapy of B-cell neoplasms.
    Petryk M; Grossbard ML
    Clin Lymphoma; 2000 Dec; 1(3):186-94; discussion 195-6. PubMed ID: 11707828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection.
    Spina M; Sparano JA; Jaeger U; Rossi G; Tirelli U
    AIDS; 2003 Jan; 17(1):137-8. PubMed ID: 12478085
    [No Abstract]   [Full Text] [Related]  

  • 29. Discordant expression of CD20 by flow cytometry and immunohistochemistry in a patient responding to rituximab: an unusual mechanism.
    Walsh KJ; Al-Quran SZ; Li Y; Braylan RC; Lynch JW
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):319-22. PubMed ID: 17324342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
    Zhou X; Hu W; Qin X
    Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
    Bienert M; Reisinger I; Srock S; Humplik BI; Reim C; Kroessin T; Avril N; Pezzutto A; Munz DL
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1225-33. PubMed ID: 15937686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.
    Foran JM; Norton AJ; Micallef IN; Taussig DC; Amess JA; Rohatiner AZ; Lister TA
    Br J Haematol; 2001 Sep; 114(4):881-3. PubMed ID: 11564080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
    Friedberg JW; Fisher RI
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.
    Bishton MJ; Leahy MF; Hicks RJ; Turner JH; McQuillan AD; Seymour JF
    Ann Oncol; 2008 Sep; 19(9):1629-33. PubMed ID: 18522934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 4. Antibody therapy for malignant lymphoma.
    Tobinai K
    Intern Med; 2007; 46(2):99-100. PubMed ID: 17220608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).
    Kang HJ; Lee SS; Kim KM; Choi TH; Cheon GJ; Kim WS; Suh C; Yang SH; Lim SM
    Asia Pac J Clin Oncol; 2011 Jun; 7(2):136-45. PubMed ID: 21585693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab in cutaneous B-cell lymphoma: a report of two cases.
    Sabroe RA; Child FJ; Woolford AJ; Spittle MF; Russell-Jones R
    Br J Dermatol; 2000 Jul; 143(1):157-61. PubMed ID: 10886152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.